(Total Views: 529)
Posted On: 11/15/2024 9:49:10 AM
Post# of 155256
Thanks, Respert.
I realize that the CD-10 and CD-12 trials were deemed as failures. However, the telling data from the long Covid trial was summarized in a Letter to the Editor to the Journal of Infection in May of this year; it's this data that I think makes sense to describe.
The link is here: https://www.journalofinfection.com/article/S0...X/fulltext
Specifically, this pair of sentences from the Letter to the Journal is of note and could be mentioned:
Drs. Norman Gaylis and Otto Yang are listed as the authors.
I realize that the CD-10 and CD-12 trials were deemed as failures. However, the telling data from the long Covid trial was summarized in a Letter to the Editor to the Journal of Infection in May of this year; it's this data that I think makes sense to describe.
The link is here: https://www.journalofinfection.com/article/S0...X/fulltext
Specifically, this pair of sentences from the Letter to the Journal is of note and could be mentioned:
Quote:
Of importance a greater numerical decrease in symptom severity score was seen for 19 of the 24 symptoms for leronlimab treated individuals compared to placebo treated individuals (Fig. 1). However, it is important to note that the trial was not powered for statistical comparisons between treatments
Drs. Norman Gaylis and Otto Yang are listed as the authors.
(12)
(0)
